Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Eşkazan A. E.

British journal of clinical pharmacology, cilt.86, ss.1790-1792, 2020 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Editöre Mektup
• Cilt numarası: 86
• Basım Tarihi: 2020
• Doi Numarası: 10.1111/bcp.14353
• Dergi Adı: British journal of clinical pharmacology
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.1790-1792
• Anahtar Kelimeler: chronic myeloid leukaemia, COVID-19, drug-drug interaction, QTc prolongation, SARS-CoV-2, tyrosine kinase inhibitor, TKI DISCONTINUATION, DRUG-INTERACTIONS, ADVERSE EVENTS, CHLOROQUINE, IMATINIB, HYDROXYCHLOROQUINE, AZITHROMYCIN, MANAGEMENT, METABOLISM, DASATINIB
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet